News | February 04, 2026
Zydus Wellness net sales up by 113.7% in Q3 FY26
Glucon-D maintained its leadership position with a 59% MAT market share
Glucon-D maintained its leadership position with a 59% MAT market share
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Subscribe To Our Newsletter & Stay Updated
